Analysts expect ObsEva SA (NASDAQ:OBSV) to post earnings of ($0.25) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ObsEva’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.28). ObsEva reported earnings per share of ($0.38) in the same quarter last year, which indicates a positive year-over-year growth rate of 34.2%. The business is expected to report its next earnings report on Thursday, August 5th.
According to Zacks, analysts expect that ObsEva will report full-year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.10) to ($0.87). For the next fiscal year, analysts expect that the business will report earnings of ($0.83) per share, with EPS estimates ranging from ($1.05) to ($0.46). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow ObsEva.
ObsEva (NASDAQ:OBSV) last announced its quarterly earnings results on Thursday, May 6th. The company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.01).
Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC grew its position in shares of ObsEva by 44.7% in the 4th quarter. Jane Street Group LLC now owns 15,848 shares of the company’s stock worth $33,000 after buying an additional 4,892 shares during the last quarter. Cutter & CO Brokerage Inc. grew its position in shares of ObsEva by 4.3% in the 1st quarter. Cutter & CO Brokerage Inc. now owns 144,550 shares of the company’s stock worth $470,000 after buying an additional 6,000 shares during the last quarter. Wedbush Securities Inc. grew its position in shares of ObsEva by 23.0% in the 1st quarter. Wedbush Securities Inc. now owns 43,525 shares of the company’s stock worth $141,000 after buying an additional 8,150 shares during the last quarter. Credit Suisse AG grew its position in shares of ObsEva by 1.5% in the 4th quarter. Credit Suisse AG now owns 596,564 shares of the company’s stock worth $1,241,000 after buying an additional 8,549 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of ObsEva in the 1st quarter worth approximately $37,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.
ObsEva Company Profile
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Featured Story: Derivative
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.